BFC Planning’s Neurocrine Biosciences NBIX Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q3
$31.2K Buy
220
+3
+1% +$482 ﹤0.01% 1796
2026
Q2
$36.6K Buy
217
+14
+7% +$2.08K ﹤0.01% 1710
2026
Q1
$26.7K Sell
203
-8
-4% -$1.06K ﹤0.01% 1585
2025
Q4
$29.9K Buy
211
+33
+19% +$4.78K ﹤0.01% 1575
2025
Q3
$25K Hold
178
– – ﹤0.01% 1469
2025
Q2
$22.4K Buy
178
+80
+82% +$9.17K ﹤0.01% 1442
2025
Q1
$10.8K Sell
98
-52
-35% -$6.59K ﹤0.01% 1731
2024
Q4
$20.5K Sell
150
-8
-5% -$989 ﹤0.01% 1450
2024
Q3
$18.2K Buy
+158
New +$21.7K ﹤0.01% 1493

Other funds holding NBIX

BFC Planning's NBIX Position: Q3 2026 in Review

BFC Planning increased its Neurocrine Biosciences (NBIX) stake by 1.4% in Q3 2026, buying an estimated $482 and bringing the position to 220 shares worth $31.2K. The position accounts for ﹤0.01% of the portfolio, ranked #1796.

BFC Planning first reported a position in NBIX in Q3 2024 and has held it in 9 quarters since. The position peaked at $36.6K in Q2 2026. 661 funds tracked by Wall St. Rank hold NBIX as of Q3 2026.

  • BFC Planning held 220 shares of Neurocrine Biosciences worth $31.2K as of Q3 2026.
  • BFC Planning bought 3 Neurocrine Biosciences shares in Q3 2026, an estimated $482.
  • Neurocrine Biosciences made up ﹤0.01% of BFC Planning's portfolio in Q3 2026, its #1796 holding.
  • BFC Planning first reported a position in Neurocrine Biosciences in Q3 2024 and has held it in 9 quarters since.
  • BFC Planning's Neurocrine Biosciences position peaked at $36.6K in Q2 2026.
  • 661 funds tracked by Wall St. Rank held Neurocrine Biosciences as of Q3 2026.

Based on BFC Planning's 13F filing for Q3 2026, filed 13 Nov 2026.